Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 12/20 | 0.55 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.37 |
| ▸ | CES2 | O00748 | 2/20 | 0.36 |
| ▸ | CES1 | P23141 | 2/20 | 0.36 |
| ▸ | CA3 | P07451 | 1/20 | 0.35 |
| ▸ | CA6 | P23280 | 1/20 | 0.35 |
| ▸ | CA5A | P35218 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.35 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.35 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL704659 | 1.00 | NFE2L2 (0.55) | NFE2L2CHEK1CES2CES1CA3 | |
| SCHEMBL7726459 | 0.84 | NFE2L2 (0.55) | NFE2L2 | |
| SCHEMBL7726452 | 0.84 | NFE2L2 (0.55) | NFE2L2 | |
| SCHEMBL705547 | 0.80 | NFE2L2 (0.55) | NFE2L2CHEK1CES2CES1CA3 | |
| SCHEMBL14604965 | 0.80 | NFE2L2 (0.55) | NFE2L2CHEK1CES2CES1CA3 | |
| SCHEMBL705546 | 0.80 | NFE2L2 (0.55) | NFE2L2CHEK1CES2CES1CA3 | |
| SCHEMBL5541438 | 0.78 | NFE2L2 (0.53) | NFE2L2CHEK1CES2CES1CA3 | |
| SCHEMBL20640997 | 0.77 | NFE2L2 (0.52) | NFE2L2CHEK1CES2CES1CA3 | |
| SCHEMBL16954656 | 0.77 | NFE2L2 (0.61) | NFE2L2CHEK1CES2CES1CA3 | |
| SCHEMBL5541428 | 0.76 | NFE2L2 (0.50) | NFE2L2CHEK1CES2CES1CA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120108577-A1 | COMPOUNDS FOR THE TREATMENT OF MULTI-DRUG RESISTANT BACTERIAL INFECTIONS | ASTRAZENECA AB (SE) | 2012-05-03 | — | — | US | disclosed |
| US-8124602-B2 | Compounds for the treatment of multi-drug resistant bacterial infections | ASTRAZENECA AB (SE) | 2012-02-28 | — | — | US | disclosed |
| US-20110092495-A1 | COMPOUNDS FOR THE TREATMENT OF MULTI-DRUG RESISTANT BACTERIAL INFECTIONS | ASTRAZENECA AB (SE) | 2011-04-21 | — | — | US | disclosed |
| EP-2289890-A1 | Compounds for the treatment of multi-drug resistant bacterial infections | AstraZeneca AB (SE) | 2011-03-02 | — | — | EP | disclosed |
| US-7875715-B2 | 6-[({1-[2-(7-methoxy-2-oxoquinoxalin-1(2H)-yl)ethyl]piperidin-4-yl}amino)methyl]-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one; antibacteria; methicillin-resistant Staphylococcus aureus (MRSA), methicillin-resistant coagulase-negative staphylococci (MRCNS), penicillin-resistant Streptococcus pneumoniae | ASTRAZENECA AB (SE) | 2011-01-25 | — | — | US | disclosed |
| US-20100152441-A1 | COMPOUNDS FOR THE TREATMENT OF MULTI-DRUG RESISTANT BACTERIAL INFECTIONS | ASTRAZENECA AB (SE) | 2010-06-17 | — | — | US | disclosed |
| US-7348434-B2 | 4-substituted quinoline derivatives, method and intermediates for their preparation and pharmaceutical compositions containing them | BIGOT ANTONY | 2008-03-25 | — | — | US | disclosed |
| EP-1893599-A1 | COMPOUNDS FOR THE TREATMENT OF MULTI-DRUG RESISTANT BACTERIAL INFECTIONS | AstraZeneca AB (SE) | 2008-03-05 | — | — | EP | disclosed |
| US-7232833-B2 | 4-substituted quinoline derivatives, method and intermediates for their preparation and pharmaceutical compositions containing them | NOVEXEL (FR) | 2007-06-19 | — | — | US | disclosed |
| WO-2006134378-A1 | COMPOUNDS FOR THE TREATMENT OF MULTI-DRUG RESISTANT BACTERIAL INFECTIONS | ASTRAZENECA AB (SE) | 2006-12-21 | — | — | WO | disclosed |
| US-20050032800-A1 | 4-Substituted quinoline derivatives, method and intermediates for their preparation and pharmaceutical compositions containing them | AVENTIS PHARMA S. A. (FR) | 2005-02-10 | — | — | US | disclosed |
| US-20040224946-A1 | 4-substituted quinoline derivatives, method and intermediates for their preparation and pharmaceutical compositions containing them | AVENTIS PHARMA S.A. (FR) | 2004-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040224946-A1 | 4-substituted quinoline derivatives, method and intermediates for their preparation and pharmaceutical compositions containing them | HRH2, HRH1, HRH3 | NFE2L2 788/4885CHEK1 1425/4885CES2 260/4885 |
| US-20050032800-A1 | 4-Substituted quinoline derivatives, method and intermediates for their preparation and pharmaceutical compositions containing them | CBR3, HRH2, HRH4 | NFE2L2 700/4885CHEK1 1494/4885CES2 74/4885 |
| US-20110092495-A1 | COMPOUNDS FOR THE TREATMENT OF MULTI-DRUG RESISTANT BACTERIAL INFECTIONS | PIGS, BPGM, IPMK | NFE2L2 1804/4885CHEK1 4625/4885CES2 2890/4885 |
| US-20120108577-A1 | COMPOUNDS FOR THE TREATMENT OF MULTI-DRUG RESISTANT BACTERIAL INFECTIONS | PIGS, BPGM, IPMK | NFE2L2 1804/4885CHEK1 4625/4885CES2 2890/4885 |
| US-20100152441-A1 | COMPOUNDS FOR THE TREATMENT OF MULTI-DRUG RESISTANT BACTERIAL INFECTIONS | PIGS, BPGM, IPMK | NFE2L2 1804/4885CHEK1 4625/4885CES2 2890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.